LTB4R2 as a Radioligand Therapy Target
LTB4R2, leukotriene B4 receptor 2, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, LTB4R2 staining is highest in kidney cancer (100% of samples positive), testicular cancer (92% of samples positive) and skin cancer (91% of samples positive). Evidence on whether LTB4R2 internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is LTB4R2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
LTB4R2 expression in cancer
Protein expression of LTB4R2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.69 | High | 100% |
| Testicular Cancer | 0.58 | High | 92% |
| Skin Cancer | 0.55 | High | 91% |
| Bladder Cancer | 0.48 | Medium | 82% |
| Endometrial Cancer | 0.48 | Medium | 64% |
| Melanoma | 0.39 | Medium | 73% |
| Glioma | 0.39 | Medium | 73% |
| Liver Cancer | 0.39 | Medium | 64% |
| Lung Cancer | 0.39 | Medium | 55% |
| Thyroid Cancer | 0.33 | Medium | 50% |
| Prostate Cancer | 0.33 | Medium | 50% |
| Breast Cancer | 0.27 | Medium | 46% |
| Cervical Cancer | 0.19 | Low | 25% |
| Ovarian Cancer | 0.12 | Low | 18% |
| Gastric Cancer | 0.12 | Low | 18% |
| Pancreatic Cancer | 0.09 | Low | 27% |
| Head and Neck Cancer | 0.08 | Low | 25% |
| Neuroendocrine Tumors | 0.08 | Low | 25% |
| Lymphoma | 0.08 | Low | 17% |
| Colorectal Cancer | 0.04 | Low | 11% |
Is LTB4R2 internalized?
Uncertain. Insufficient literature found.
LTB4R2 clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for LTB4R2 yet. Search ClinicalTrials.gov for LTB4R2 trials.
LTB4R2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See LTB4R2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
LTB4R2 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.20 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how LTB4R2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.